Bayer confirms plans for 50% Russian localization by 2025

9 July 2019

German pharma major Bayer (BAYN: DE) has confirmed its plans to localize 50% of its drugs production in Russia by 2025, according to recent statements by Niels Hessmann, general representative of Bayer in Russia and the CIS region, reports The Pharma Letter’s local correspondent.

It is planned that the production of the majority of these drugs will take place at the capacities of Bayer’s main partner in Russia – the St Petersburg drugmaker Polysan.

As part of these plans, Bayer aims to launch the production of some of its drugs designed for the treatment of cardiovascular diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK